Report Name: Celgene Profile – Overview, History, SWOT Analysis, Products/Services, Facts, Financials, Key Executives, Competitors, Tech Intelligence, IT Outsourcing, IT Management, Recent Developments and Strategy Evaluation
Celgene Report – Publisher: Research Cosmos
Price Scheme of the Report:
Single User License – USD 150
Team License – USD 175
Corporate License – USD 250
Celgene – Business Description:
Celgene is a global integrated biopharmaceutical company. It is engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. The company operates in the US, Europe and other countries. Celgene’s marketed products include Revlimid, Pomalyst/Imnovid, Abraxane, Vidaza, Otezla, Thalomid, Azacitidine for injection, and Istodax. Revlimid (lenalidomide) is an oral immunomodulatory drug marketed in the US and many international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma and for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS). As of December 2016, the Revlimid segment recorded revenues of $6,973.6 million, an increase of 20.2% over FY2015. Pomalyst/Imnovid is a proprietary, distinct, small molecule that is administered orally and modulates the immune system and other biologically important targets. It received its first approvals from the FDA and the EC. The Pomalyst/Imnovid segment recorded revenues of $1,310.7 million in FY2016, an increase of 33.3% over FY2015. Abraxane (paclitaxel albumin-bound particles for injectable suspension) is a solvent-free chemotherapy treatment option for metastatic breast cancer. The company developed Abraxane using its proprietary nab technology platform. Abraxane is is approved for the treatment of patients with metastatic breast; non-small cell lung cancer; pancreatic cancer, unresectable pancreatic cancer and gastric cancer. The Abraxane segment recorded revenues of $973.4 million in FY2016, an increase of 0.6% over FY2015. Vidaza (azacitidine for injection) is a pyrimidine nucleoside analog that has been shown to reverse the effects of DNA hypermethylation and promote subsequent gene re-expression. Vidaza is a Category 1 recommended treatment for patients with intermediate-2 and high-risk MDS. The Vidaza segment recorded revenues of $608 million in FY2016, a decrease of 2.9% over FY2015. Otezla is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate. It is used for the treatment of patients with psoriasis and psoriatic arthritis. The Otezla segment recorded revenues of $1,017.2 million in FY2016, an increase of 115.6% over FY2015. Thalomid (thalidomide) is marketed for patients with newly diagnosed multiple myeloma and erythema nodosum leprosum. The Thalomid segment recorded revenues of $152.1 million in FY2016, a decrease of 18% over FY2015. Azacitidine for injection (Vidaza) is a pyrimidine nucleoside analog that has been shown to reverse the effects of DNA hypermethylation and promote subsequent gene re-expression. It is a Category 1 recommended treatment for patients with intermediate-2 and high-risk MDS, according to the National Comprehensive Cancer Network and is marketed in the US for the treatment of all subtypes of MDS. The Azacitidine for injection segment recorded revenues of $66 million in FY2016, a decrease of 21.3% over FY2015. Istodax (romidepsin) is used for the treatment of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). Istodax has received Orphan Drug designation for the treatment of non-Hodgkin’s T-cell lymphomas, which include CTCL and PTCL from the European Agency for the Evaluation of Medicinal Products (EMA). The Istodax segment recorded revenues of $79.3 million in FY2016, an increase of 14.8% over FY2015. Celgene also derives revenues from a licensing agreement with Novartis, which entitles the company to royalties on Focalin XR and the entire Ritalin family of drugs, and sales of bio-therapeutic products and services through its Cellular Therapeutics subsidiary. Geographically, the US, Celgene Corporation’s largest geographical market, accounted for 62.4% of the total revenues in FY2016. Revenues from the US reached $7,009.5 million in FY2016, an increase of 22.1% over FY2015. Europe accounted for 27.1% of the total revenues in FY2016. Revenues from Europe reached $3,046.4 million in FY2016, an increase of 16.1% over FY2015. Other accounted for 10.4% of the total revenues in FY2016. Revenues from other reached $1,173.3 million in FY2016, an increase of 14.2% over FY2015.
Scope of the Report:
About the Company: Historical Details, Current Ownership Structure and basic overview of Balfour Beatty plcin terms of revenue, net income, and operating income.
Financials: Details about Balfour Beatty plclisting status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.
Products/Services: Listing of the company’s entire portfolio along with the description of individual products/services providing a clear picture of their target audience.
Company SWOT Analysis: Outlines Atea ASA.’s strengths, weaknesses, and opportunities and threats facing the company.
Recent Developments: Showcases Atea ASA.’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.
Strategic Evaluation: This section provides an overview of Atea ASA.’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.
Technology Landscape: Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken by the company at present along with outlook.
Key Questions Answered
What domain does Balfour Beatty plcoperate and what are key points about it?
What is the product/service portfolio of Atea ASA.?
How has Balfour Beatty plcperformed financially from 2013?
How does Balfour Beatty plcrank among its peers in terms of revenue and market share?
What are Balfour Beatty plcstrengths and weaknesses and what opportunities and threats do it face?
What are Atea ASA.’s main growth strategies and how successful has the company been at implementing them?
What is the in-house technical capability of Atea ASA.? Where does it procure/outsource it?
Reasons to buy
Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own
Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at a very competitive cost
12 hour delivery time fulfilling your urgent requests as per your requirement
On-demand customization options that can completely cater to your needs by focusing the report on given specifics
For More Information, Get Sample of the report:Request Sample
Got Some Questions? Inquire Here:Inquire Before Buying
Get This Report:Purchase Now
For More Details, Contact Provider Directly:
+1 888 709 8757